Vedanta Biosciences said it significantly reduced its workforce and refocused resources on advancing VE303, an eight‑strain live bacterial consortium in Phase 3 for prevention of recurrent Clostridioides difficile infection. The company cited strong Phase 2 data and a strategic need to conserve capital amid challenging funding conditions, pausing other programs after prior failures and earlier layoffs. Vedanta plans to complete the Phase 3 study by mid‑2027 and is seeking additional financing to support the pivotal program. The move echoes consolidation trends among microbiome companies chasing single, high‑value assets.